Related Experiment Video
Updated: Jul 15, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
From bench to bedside: the application of cannabidiol in glioma
Shiying Feng1,2, Yuanming Pan3, Pu Lu1
1Department of Oncology, Baotou City Central Hospital, Baotou, 014040, China.
Abstract:
Glioma is the most common malignant tumor in central nervous system, with significant health burdens to patients. Due to the intrinsic characteristics of glioma and the lack of breakthroughs in treatment modalities, the prognosis for most patients remains poor. This results in a heavy psychological and financial load worldwide. In recent years, cannabidiol (CBD) has garnered widespread attention and research due to its anti-tumoral, anti-inflammatory, and neuroprotective properties. This review comprehensively summarizes the preclinical and clinical research on the use of CBD in glioma therapy, as well as the current status of nanomedicine formulations of CBD, and discusses the potential and challenges of CBD in glioma therapy in the future.
Insights
Cannabidiol (CBD) shows promise for treating brain tumors like glioma, offering anti-tumor and neuroprotective effects. Further research into CBD and nanomedicine may improve outcomes for glioma patients.
Area of Science:
- Neuro-oncology
- Pharmacology
- Nanomedicine
Background:
- Glioma represents the most prevalent central nervous system malignancy, imposing substantial health burdens.
- Current glioma treatment modalities lack significant breakthroughs, leading to poor patient prognoses.
- The psychological and financial toll on patients and families is considerable.
Purpose of the Study:
- To review preclinical and clinical research on cannabidiol (CBD) for glioma therapy.
- To summarize the current status of nanomedicine formulations of CBD in glioma treatment.
- To discuss the future potential and challenges of using CBD in managing glioma.
Main Methods:
- Comprehensive literature review of preclinical studies on CBD in glioma models.
- Analysis of clinical trial data investigating CBD efficacy and safety in glioma patients.
- Evaluation of research on nanomedicine approaches for enhanced CBD delivery in brain tumors.
Main Results:
- CBD exhibits demonstrated anti-tumoral, anti-inflammatory, and neuroprotective properties relevant to glioma.
- Preclinical data suggest CBD's potential to inhibit glioma cell proliferation and induce apoptosis.
- Nanomedicine formulations are being explored to improve CBD's bioavailability and brain penetration.
Conclusions:
- Cannabidiol (CBD) presents a promising therapeutic candidate for glioma treatment.
- Further clinical investigation and optimized nanomedicine delivery systems are crucial for realizing CBD's full potential.
- Addressing challenges in delivery and efficacy will be key to integrating CBD into future glioma management strategies.
